{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:58:31Z","timestamp":1791291511566,"version":"4.3.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009948","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T00:00:00Z","timestamp":1416182400000}}],"reference-count":58,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009948.pub2","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T09:40:10Z","timestamp":1416217210000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer"],"prefix":"10.1002","volume":"2014","author":[{"given":"Zu-Yao","family":"Yang","sequence":"first","affiliation":[{"name":"The Chinese University of Hong Kong; Division of Epidemiology, The Jockey Club School of Public Health and Primary Care; Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"The Chinese University of Hong Kong; Division of Epidemiology, The Jockey Club School of Public Health and Primary Care; Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Mao","sequence":"additional","affiliation":[{"name":"The Chinese University of Hong Kong; Division of Epidemiology, The Jockey Club School of Public Health and Primary Care; Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yin","family":"Wu","sequence":"additional","affiliation":[{"name":"The Chinese University of Hong Kong; Division of Epidemiology, The Jockey Club School of Public Health and Primary Care; Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Fang","family":"Huang","sequence":"additional","affiliation":[{"name":"The Chinese University of Hong Kong; Division of Epidemiology, The Jockey Club School of Public Health and Primary Care; Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Feng","family":"Hu","sequence":"additional","affiliation":[{"name":"The Chinese University of Hong Kong; Division of Epidemiology, The Jockey Club School of Public Health and Primary Care; Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ling","family":"Tang","sequence":"additional","affiliation":[{"name":"The Chinese University of Hong Kong; Division of Epidemiology, The Jockey Club School of Public Health and Primary Care; Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,11,17]]},"reference":[{"key":"10.1002\/14651858.CD009948.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1200\/JCO.2007.13.0856","article-title":"Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer","volume":"25","author":"Butts","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD009948.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2009.21.9618","article-title":"Cetuximab and first-line taxane\/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099","volume":"28","author":"Lynch","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"9674","key":"10.1002\/14651858.CD009948.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"The Lancet"},{"issue":"2","key":"10.1002\/14651858.CD009948.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mdm474","article-title":"Randomized phase II study of cetuximab plus cisplatin\/vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer","volume":"19","author":"Rosell","year":"2008","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD009948.pub2-BIB0005|cit5","first-page":"904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"Journal of Clinical\u00a0Oncology"},{"issue":"9","key":"10.1002\/14651858.CD009948.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/cncr.23902","article-title":"Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study","volume":"113","author":"Belani","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1002\/14651858.CD009948.pub2-BIB0007|cit7","first-page":"1286","article-title":"Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017","volume":"3","author":"Borghaei","year":"2008","journal-title":"Journal\u00a0of\u00a0Thoracic Oncology"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0008|cit8","unstructured":"Maione P Mencoboni M Carrozza F Vigano MG Gebbia V Verusio C Addition of cetuximab (C) to gemcitabine (G) in elderly or performance status 2 (PS) patients (pts) with advanced non small-cell lung cancer (NSCLC): The calc1 randomised phase 2 trials Annals of Oncology 2008 ix24 ix32"},{"issue":"1","key":"10.1002\/14651858.CD009948.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2009.03.021","article-title":"Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials","volume":"67","author":"Gridelli","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0010|cit10","unstructured":"NCT00085501 S0342: Paclitaxel, carboplatin, and cetuximab in treating patients with stage IIIB or stage IV non-small cell lung cancer www.clinicaltrials.gov\/show\/NCT00085501"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0011|cit11","unstructured":"NCT00097214 Carboplatin plus cetuximab for treatment of stage IIIB\/IV non-small cell lung cancer (NSCLC) www.clinicaltrials.gov\/show\/NCT00097214"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0012|cit12","unstructured":"NCT00103207 Cetuximab in treating patients with recurrent or stage IIIB or stage IV lung cancer www.clinicaltrials.gov\/show\/NCT00103207"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0013|cit13","unstructured":"NCT00112294 Study of taxane\/carboplatin +\/- cetuximab as first-line treatment for patients with advanced\/metastatic non-small cell lung cancer www.clinicaltrials.gov\/show\/NCT00112294"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0014|cit14","unstructured":"NCT00118118 Cetuximab in treating patients with recurrent or progressive metastatic non-small cell lung cancer www.clinicaltrials.gov\/show\/NCT00118118"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0015|cit15","unstructured":"NCT00148798 Study of cisplatin\/vinorelbine +\/- cetuximab as first-line treatment of advanced non small cell lung cancer (FLEX) www.clinicaltrials.gov\/show\/NCT00148798"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0016|cit16","unstructured":"NCT00165334 Cetuximab and vinorelbine in elderly subjects with lung cancer www.clinicaltrials.gov\/show\/NCT00165334"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0017|cit17","unstructured":"NCT00193453 Gemcitabine, docetaxel, and cetuximab in patients with unresectable advanced non-small cell lung cancer www.clinicaltrials.gov\/show\/NCT00193453"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0018|cit18","unstructured":"NCT00216203 Pemetrexed plus cetuximab in patients with recurrent non small cell lung cancer www.clinicaltrials.gov\/show\/NCT00216203"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0019|cit19","unstructured":"NCT00828841 Phase 2b study of cetuximab with platinum-based chemo as first line treatment of recurrent or advanced NSCLC www.clinicaltrials.gov\/show\/NCT00828841"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0020|cit20","unstructured":"NCT01004731 Study of anti-epidermal growth factor receptor (EGFr) antibody, cetuximab, in combination with gemcitabine\/carboplatin in patients with stage IV lung cancer www.clinicaltrials.gov\/show\/NCT01004731"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Pirker R Szczesna A Von Pawel J Krzakowski M Ramlau R Park K FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin\/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) [Abstract No. 3] Journal of Clinical Oncology: ASCO annual meeting proceedings 2008","DOI":"10.1200\/jco.2008.26.15_suppl.3"},{"issue":"36","key":"10.1002\/14651858.CD009948.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1200\/JCO.2004.00.1438","article-title":"Phase I\/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer","volume":"23","author":"Robert","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Rosell R Ramlau R Szczesna A Daniel C Bertrand M Garcia AR Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and cinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC) [abstract] European Journal of Cancer: ECCO III European Cancer Conference; 2003 Sept 21-25; Copenhagen, Denmark 2003","DOI":"10.1016\/S1359-6349(03)90090-5"},{"issue":"3","key":"10.1002\/14651858.CD009948.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3816\/CLC.2010.n.026","article-title":"Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer","volume":"11","author":"Spigel","year":"2010","journal-title":"Clinical Lung Cancer"},{"issue":"2","key":"10.1002\/14651858.CD009948.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/07357900903286958","article-title":"A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer","volume":"28","author":"Stinchcombe","year":"2010","journal-title":"Cancer Investigation"},{"issue":"34","key":"10.1002\/14651858.CD009948.pub2-BIB0026|cit26","first-page":"8786","article-title":"Multicenter phase I\/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer","volume":"23","author":"Thienelt","year":"2005","journal-title":"Journal of Clinical\u00a0Oncology"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0027|cit27","unstructured":"Von Pawel J Park K Phase III study comparing cisplatin\/vinorelbine plus cetuximab versus cisplatin\/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX) Journal of Clinical Oncology: ASCO annual meeting proceedings. 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 June 2-6; Atlanta, GA 2006"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0028|cit28","unstructured":"NCT00946712 S0819: Carboplatin\/paclitaxel with or without bevacizumab and\/or cetuximab in stage IV or recurrent non-small cell lung cancer www.clinicaltrials.gov\/show\/NCT00946712"},{"issue":"17","key":"10.1002\/14651858.CD009948.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1200\/JCO.2010.31.7875","article-title":"Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA\/B non-small-cell lung cancer: RTOG 0324","volume":"29","author":"Blumenschein","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0030|cit30","unstructured":"Butts Study of Gemcitabine\/Platinum +\/- Cetuximab as First-Line Treatment for Patients With Advanced\/Metastatic Non-Small Cell Lung Cancer http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00112346 2005"},{"issue":"1","key":"10.1002\/14651858.CD009948.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-154-1-201101040-00006","article-title":"Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer","volume":"154","author":"Dahabreh","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"25","key":"10.1002\/14651858.CD009948.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0033|cit33","unstructured":"FDA Final Labeling Text (bevacizumab) www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125085s0169lbl.pdf"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0034|cit34","unstructured":"FDA Gefitinib (marketed as Iressa) Information www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm110473.htm"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0035|cit35","unstructured":"FDA 2010 Highlights for Prescribing Information (Tarceva) www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021743s14s16lbl.pdf"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0036|cit36","unstructured":"FDA FDA Approves Erbitux to Treat Late-Stage Head and Neck Cancer www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm278894.htm"},{"issue":"28","key":"10.1002\/14651858.CD009948.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0038|cit38","unstructured":"McMaster University GRADEpro 3.6 2014"},{"issue":"3","key":"10.1002\/14651858.CD009948.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/annonc\/mdh087","article-title":"Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel","volume":"15","author":"Gridelli","year":"2004","journal-title":"Annals of Oncology"},{"issue":"7651","key":"10.1002\/14651858.CD009948.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"Rating quality of evidence and strength of recommendations: What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"British Medical Journal"},{"issue":"31","key":"10.1002\/14651858.CD009948.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1200\/JCO.2009.27.9356","article-title":"Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342","volume":"28","author":"Herbst","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0042|cit42","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0043|cit43","unstructured":"International Agency for Research on Cancer Fast stats: most frequent cancers www.globocan.iarc.fr\/factsheets\/populations\/factsheet.asp?uno=900"},{"issue":"5","key":"10.1002\/14651858.CD009948.pub2-BIB0044|cit44","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"8","key":"10.1002\/14651858.CD009948.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/cncr.24148","article-title":"A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory\/resistant patients with advanced nonsmall cell lung cancer","volume":"115","author":"Kim","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD009948.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2010.01.009","article-title":"Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis","volume":"70","author":"Lin","year":"2010","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1002\/14651858.CD009948.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1378\/chest.106.3.861","article-title":"Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature","volume":"106","author":"Marino","year":"1994","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD009948.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller AB","year":"1981","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD009948.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1470-2045(11)70194-2","article-title":"Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?","volume":"12","author":"Mitsudomi","year":"2011","journal-title":"The Lancet Oncology"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0050|cit50","unstructured":"National Cancer Institute FDA Approval for Cetuximab www.cancer.gov\/cancertopics\/druginfo\/fda-cetuximab"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1748-717X-7-3","article-title":"A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer","volume":"7","author":"Nieder","year":"2012","journal-title":"Radiation Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009948.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(11)70318-7","article-title":"EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study","volume":"13","author":"Pirker","year":"2012","journal-title":"The Lancet Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009948.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/0194599811399559","article-title":"Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data","volume":"144","author":"Reeves","year":"2011","journal-title":"Otolaryngology-Head and Neck Surgery"},{"key":"10.1002\/14651858.CD009948.pub2-BIB0054|cit54","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"2","key":"10.1002\/14651858.CD009948.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009948.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1513\/pats.200809-110LC","article-title":"Current treatments for advanced stage non-small cell lung cancer","volume":"6","author":"Stinchcombe","year":"2009","journal-title":"Proceedings of the American Thoracic Society"},{"issue":"3","key":"10.1002\/14651858.CD009948.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD009948.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.clinthera.2010.03.012","article-title":"Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review","volume":"32","author":"Tol","year":"2010","journal-title":"Clinical Therapeutics"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009948.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T16:32:08Z","timestamp":1699720328000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009948.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Lung Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,11,17]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009948.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,17]]}}}